Abstract :

Background: Type 2 Diabetes Mellitus (T2DM) is one of the chronic metabolic diseases with a prevalence that continues to increase globally. This disorder not only affects glucose metabolism but also causes multisystem complications, including neurological complications such as peripheral neuropathy, autonomic dysfunction, and cognitive impairment.

Objective: This study aims to comprehensively analyze the latest empirical evidence regarding the relationship between type 2 diabetes (DMT2) and the risk of neurological complications.

Methods: This study uses a Systematic Literature Review (SLR) approach following the PRISMA method.

Results: The findings indicate that DMT2 patients have a higher risk of developing neurological complications, both peripheral and central. Certain antidiabetic medications, such as SGLT2 inhibitors and GLP-1 receptor agonists, show protective effects in reducing the risk of dementia and neurodegeneration. Additionally, factors such as disease duration, age at diagnosis, and genetic status (e.g., APOE ε4) also contribute to variations in risk levels. Non-pharmacological interventions, such as regular physical activity and good metabolic control, have also been shown to improve cognitive function and slow the progression of neuropathy.

Conclusion: Based on the study results, DMT2 significantly increases the risk of neurological complications through mechanisms of inflammation, oxidative stress, and insulin resistance that affect nerve tissues. Pharmacological interventions with modern agents such as GLP-1 agonists and SGLT2 inhibitors show protective prospects against neurodegeneration.

---

Keywords :

Complication Prevention, Metabolic Risk, Nerve Pathogenesis, Neurological Complications, Type 2 Diabetes Mellitus

---

References :

1. Zhou P, Zhou J, Li J, Qin L. Prevalence and risk factors for painful diabetic peripheral neuropathy : a systematic review and meta-analysis. Front Neurol. 2025;(Dm).
2. Rashtchian A, Etemadi MH, Asadi E, Binaei S, Abbasi M, Bayani M, et al. Diabetes mellitus and risk of incident dementia in APOE ɛ 4 carriers : an updated meta ‑ analysis. BMC Neurosci. 2024;1–10.
3. Kciuk M, Kruczkowska W, Gałeziewska J, Wanke K, Zaneta˙Kałuzinska-Kołat, Aleksandrowicz M, et al. Alzheimer ’ s Disease as Type 3 Diabetes : Understanding the Link and Implications. Int J Mol Sci. 2024;
4. Wang J, Shen D, Wang K, Diao Z, Huang X, Li J. Meta-Radiology Potential neural mechanisms and imaging changes in type 2 diabetes with cognitive impairment. Meta-Radiology. 2025;3(3):100149.
5. Lin H tang, Tsai Y fong, Liao P lun, Wei JC chung. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025;8(7):1–14.
6. Bodman MA, Dreyer MA, Varacallo MA. Diabetic peripheral neuropathy. In: StatPearls [Internet]. StatPearls Publishing; 2024.
7. Seo DH, Kim M, Cho Y, Ahn SH, Hong S, Kim SH. Association between Age at Diagnosis of Type 2 Diabetes and Subsequent Risk of Dementia and Its Major Subtypes. J Clin Med. 2024;
8. Seminer A, Mulihano A, O’Brien C, Krewer F, Costello M, Judge C, et al. Cardioprotective Glucose-Lowering agents and dementia risk: A systematic review and Meta-Analysis. JAMA Neurol. 2025;
9. Tang B, Sjölander A, Wastesson JW, Maura G, Blotiere P olivier, Szilcz M, et al. Comparative effectiveness of glucagon-like peptide-1 agonists , dipeptidyl peptidase-4 inhibitors , and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden : an emulated trial study. eClinicalMedicine. 2024;73:102689.
10. Lu H huan, Zhou Y, Chen C, Gu Z juan. Meta-analysis of the effect of exercise intervention on cognitive function in elderly patients with type 2 diabetes mellitus. BMC Geriatr. 2024;
11. Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes : population based cohort study. 2024;1–12.
12. Kim J, Han K Do, Lee JY, Yang YS, Cheon DY, Lee JJ, et al. Diabetes status , duration , and risk of dementia among ischemic stroke patients. Alzheimers Res Ther. 2025;
13. Wang J, Shen D, Wang K, Diao Z, Huang X, Li J. Potential neural mechanisms and imaging changes in type 2 diabetes with cognitive impairment. Meta-Radiology. 2025;3(3):100149.
14. Zhao Y, Wang2 H, Tang G, Wang L, Tian X, Li R. Risk factors for mild cognitive impairment in type 2 diabetes : a systematic review and meta-analysis. 2025;(June):1–17.
15. Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with Alzheimer’s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study. 2025;106(4):1509–22.
16. Giorgi R De, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, et al. Articles 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes : a propensity-score matched cohort study. eClinicalMedicine. 2024;74:102726.